Corrected QT (QTc) =< 480 msec\r\n* Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; If possible, alternative agents should be considered\r\n* Patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Correct QT interval (QTc) =< 480 msec; Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause torsades de pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Patients who are receiving drugs that prolong QTc are not eligible
Corrected QT (QTc) interval =< 480 milliseconds; Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Family history of long QT syndrome, with a QTc interval greater than (>) 480 millisecond (msec) at screening, or taking concurrent medications known to prolong QT/QTc interval
Current use of drugs that are known to prolong QT interval
Current use of drugs that are known to prolong the QT interval
Every effort must be made to avoid the use of a concomitant medication that can prolong the corrected QT (QTc) interval while receiving selumetinib (hyd-sulfate AZD6244); if the patient cannot discontinue medications that prolong QTc interval while receiving selumetinib, close cardiac monitoring should be performed
Patients who are on treatment with drugs known to prolong the QT/QTc interval.
Uncorrectable electrolyte abnormalities, long QT syndrome or taking medications known to prolong the QT interval
Current treatment with medications that are well known to prolong the QT interval
Patients who are on treatment with drugs known to prolong the QT/QTc interval.
Subjects receiving concomitant medications that prolong corrected QT interval (QTc)
Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Required use of a concomitant medication that can prolong the QT interval
Treatment with medications that can prolong the QTc interval within the last 2 weeks
Use of drugs that could prolong the QT interval within 7 days before the start of study therapy.
Any medications that are known to prolong the QTc interval.
Current treatment with medications that are well known to prolong the Q-wave/T-wave (QT) interval
Use of a drug known to prolong the cardiac QT interval.
Patients taking medications that have the potential to prolong the QT interval
Planned concomitant use of medications known to prolong the QT/QTc interval
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients with a mean QTcF interval of > 500 msec or receiving therapeutic agents known to prolong the QT interval
Taking medications that are known to prolong the QT interval unless they can be transferred to other medications within ?5 half-lives prior to dosing (If equivalent medication is not available QTc will be closely monitored)
Required use of a concomitant medication that can prolong the QT interval
Unable or unwilling to discontinue concomitant use of drugs that are known to prolong the QT interval.
Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication.
Concurrent therapy with medications known to prolong the QT interval and/or associated with Torsade de Pointes arrhythmia
Current treatment with agents that may prolong QT interval and may cause Torsade de Points which cannot be discontinued at least five half-lives prior to treatment
Medications known to prolong corrected QT (QTC) are not allowed
Current or planned use of agents that prolong or suspected to prolong QTc
Ponatinib\r\n* Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment\r\n* Discontinuation of any medications known to contribute significantly to the risk of QT prolongation at least 48 hours prior to start of study drug; Levaquin and Zofran are an exception; of note, certain agents that prolong the corrected QT interval (QTc) may be allowed but only after discussion with the chemotherapy pharmacist; should the investigator believe that therapy with a potentially QT prolonging medication is vital to an individual subject’s care, then additional electrocardiograms (ECGs) should be done at the investigator’s discretion to ensure the subject’s safety\r\n* Serum lipase =< 1.5 x ULN\r\n* Serum amylase =< 1.5 x ULN
Patients must not be receiving other medications known to prolong the QT interval at the time of study entry or while on protocol therapy
Patients who are on treatment with drugs known to prolong the QT/QTc interval.
Patients who have a mean corrected QT (QTc) interval > 450 ms at base line will be excluded; concomitant use of agents that prolong the QT interval will be avoided
The use of concomitant medications that prolong the QT/QTc interval.
Patients receiving medications that have the potential to prolong the QT interval
Patients must not be planning to receive any concomitant medication known to prolong QT interval
Patients must not be taking within 7 days prior to sub-study registration, nor plan to take while on protocol treatment drugs that are known to prolong the QT interval
Patients who are receiving drugs that prolong the QTc are not eligible
Concomitant medication(s) known to increase the QT interval
Patients taking medications that are known to prolong the QT interval
Patients taking medications that are known to prolong the QT interval unless they can be transferred to other medications within ?5 half-lives prior to dosing, or unless the medications can be properly monitored during the study.
Patient must not be taking drugs known to prolong the QTc interval; such drugs should be discontinued at least 5 half-lives prior to randomization
Patients who require use of a concomitant medication that can prolong the QT interval
Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval
Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication
Current use of drugs that are known to prolong the QT interval
Patient may not be taking any drugs that prolong the QT/QTc interval; if patient is on any of these drugs, patient may enroll in the study if the drugs can be discontinued for at least 5 half-lives prior to the first dose of tosedostat and capecitabine
Patient requires the use of concomitant medications that are contraindicated with cardiac glycosides and/or are known to prolong the QT/QTc interval during study participation (see Appendix 2).
Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g. within 5 half-lives or 7 days prior to starting study drug)
Other medications known to prolong QT interval should be discontinued and if not possible, patient is excluded from this study
Concurrent treatment with any agent known to prolong the corrected QT (QTc) interval
Subjects taking medications that are known to prolong the QT interval (see Section 9.11.3).
Current use of drugs that are known to prolong the QT interval
Current use of drugs known to prolong the QTc interval including class Ia and III antiarrhythmics or history of congenital long QTc syndrome
Planned concomitant use of medications known to prolong the QT/QTc interval
Subjects taking medications that are known to prolong the QT interval unless they can be transferred to other medications within ?5 half-lives prior to dosing.
Use of medications that are known to prolong cause QT prolongation
Current use of drugs that are known to prolong the QT interval
the potential to prolong the QT interval, or
Congenital long QT syndrome or subjects taking concomitant medications known to prolong the QT interval (e.g., tricyclics, azithromycin, methadone).
Subject is taking medication known to prolong the QT interval.
Caution should be used if patients are required to use a concomitant medication that can prolong the QT interval and efforts should be made to switch to a different medication before the patient begins treatment under an experimental arm
Subjects taking medications that are known to prolong the QT interval
Patients taking medications known to prolong the QTc interval directly or that interact pharmacodynamically with medicines to prolong the QTc interval.
Ongoing treatment with any drugs known to prolong the QTc interval, including anti-arrhythmic medications (stable regimen of antidepressants of the selective serotonin reuptake inhibitor (SSRI) class is allowed))
Patients who are receiving drugs that prolong the QTc are not eligible
Use of a concomitant medication that can prolong the QT interval is strongly discouraged and patients should be advised to discontinue use of these medications during the study period and alternatives selected when indicated
Patients with a mean QTc interval greater than 480ms are excluded. Avoid concomitant administration of agents that prolong the QT interval, except at the discretion of the investigator. If advised, patients should discontinue the use of these agents at least 2 weeks before the study begins. No uncontrolled arrhythmias.
Patients may not be receiving any medications that are known to prolong QT interval unless reviewed and approved by the principal investigator (PI)
Risk factors for torsades de pointes such as:\r\n* Uncontrolled hypokalemia\r\n* Uncontrolled hypomagnesemia or hypermagnesemia\r\n* Cardiac failure (New York Heart Association class II or higher)\r\n* Clinically significant/symptomatic bradycardia (hear rate [HR] < 50), or high-grade atrioventricular (AV) block\r\n* Known diagnosis of QT prolongation (QTc >= 470) or family history of long QT syndrome\r\n* Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), human immunodeficiency virus [HIV], cirrhosis, uncontrolled hypothyroidism or cardiac failure\r\n* Concomitant medications known to prolong the QT interval during the same time as pasireotide is to be administered (unless approved by principal investigator [PI] and QTc < 470; standard transplant medications that are known to prolong the QT (e.g. azoles, ondansetron, etc.) are permitted but caution is advised and patients should be closely monitored)
Current treatment with medications known to prolong the QT interval Stage I:
Patients on medications that prolong QT interval, per principal investigator (PI) discretion
Co-administration of drugs that prolong QT interval, cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers, or other investigational agents (a wash-out period of five times the half life of drugs that prolong QT will be allowed with approval of prescriber)
Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval
Participants taking any drug known to prolong QTc interval within at least 2 weeks before the start of the study drug and during the conduct of the study